Incyte (INCY) Q3 Earnings Miss Estimates
Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago.
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chron...
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment –...
Doğuş Technology and Doğuş Construction Participate in ConteQ Expo 2024 with Innovative Projects
DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, ...
Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License App...
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host...
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
Incyte (INCY) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of $0.78. This compares to earnings of $0.99 per share a year ago.
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.
INCY or MYGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for...
Incyte: The Worst Has Been Avoided
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completio...
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.
Related Companies